Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab in locally advanced esophageal squamous cell carcinoma
NCT05520619Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2022
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sun Yat-sen University. Started Sep 2022; status: active, not recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05520619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05520619.